Clinical Trials Browser

Active not recruiting × Carcinoma, Transitional Cell × tazemetostat × Clear all

NCT03854474 2026-05-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell